Language:

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

The New England journal of medicine, 2012-05, Vol.366 (19), p.1759-1769 [Peer Reviewed Journal]

Copyright © 2012 Massachusetts Medical Society. All rights reserved. ;2015 INIST-CNRS ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1112704 ;PMID: 22571200 ;CODEN: NEJMAG

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Author: Palumbo, Antonio ; Hajek, Roman ; Delforge, Michel ; Kropff, Martin ; Petrucci, Maria Teresa ; Catalano, John ; Gisslinger, Heinz ; Wiktor-Jędrzejczak, Wiesław ; Zodelava, Mamia ; Weisel, Katja ; Cascavilla, Nicola ; Iosava, Genadi ; Cavo, Michele ; Kloczko, Janusz ; Bladé, Joan ; Beksac, Meral ; Spicka, Ivan ; Plesner, Torben ; Radke, Joergen ; Langer, Christian ; Yehuda, Dina Ben ; Corso, Alessandro ; Herbein, Lindsay ; Yu, Zhinuan ; Mei, Jay ; Jacques, Christian ; Dimopoulos, Meletios A
Subjects: Administration, Oral ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Clinical trials ; Disease-Free Survival ; Dose-response relationship (Biochemistry) ; Double-Blind Method ; Drug therapy ; Drugs ; Female ; Follow-Up Studies ; General aspects ; Hematologic and hematopoietic diseases ; Humans ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulinopathies ; Immunomodulation ; Immunopathology ; Induction Chemotherapy ; Induction therapy ; Kaplan-Meier Estimate ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Maintenance Chemotherapy ; Male ; Medical sciences ; Melphalan ; Melphalan - administration & dosage ; Melphalan - adverse effects ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Multiple Myeloma - mortality ; Neoplasms, Second Primary - epidemiology ; Neutropenia ; Neutropenia - chemically induced ; Patients ; Prednisone ; Prednisone - administration & dosage ; Prednisone - adverse effects ; Product/Service Evaluations ; Survival ; Thalidomide - administration & dosage ; Thalidomide - adverse effects ; Thalidomide - analogs & derivatives ; Transplantation ; Transplants & implants ; Tumors
Is Part Of: The New England journal of medicine, 2012-05, Vol.366 (19), p.1759-1769
Description: Patients treated with an induction regimen of melphalan, prednisone, and lenalidomide followed by lenalidomide maintenance therapy had longer progression-free survival than those who did not receive maintenance therapy. Melphalan–prednisone (MP) has long been the treatment of choice for patients with multiple myeloma who are older than 65 years of age. 1 The introduction of new agents in the past few years has substantially changed the treatment of multiple myeloma. MP plus either thalidomide or bortezomib is reported to improve progression-free survival and overall survival, as compared with MP alone, 2 , 3 and these combinations are now considered the new standards of care for elderly patients with newly diagnosed multiple myeloma who are ineligible for stem-cell transplantation. 1 Lenalidomide in combination with dexamethasone is effective in relapsed or refractory multiple myeloma 4 – . . .
Publisher: Waltham, MA: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
EISSN: 1533-4406
DOI: 10.1056/NEJMoa1112704
PMID: 22571200
CODEN: NEJMAG
Source: ProQuest One Psychology
AUTh Library subscriptions: ProQuest Central
MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

Copyright © 2012 Massachusetts Medical Society. All rights reserved. ;2015 INIST-CNRS ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1112704 ;PMID: 22571200 ;CODEN: NEJMAG

Searching Remote Databases, Please Wait